<DOC>
	<DOC>NCT01861197</DOC>
	<brief_summary>Efficacy of Dovitinib for Squamous NSCLC.</brief_summary>
	<brief_title>Phase II Study of Dovitinib for FGFR1 Amplified Squamous Non-small Cell Lung Cancer</brief_title>
	<detailed_description />
	<criteria>histologically confirmed squamous NSCLC Previously treated with one or two lines of chemotherapy FGFR amplification (FISH &gt; 5 copies of genes) 20 years or older ECOG PS 02 active infection uncontrolled brain metastasis unstable angina or MI</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>Efficacy</keyword>
	<keyword>Dovitinib</keyword>
	<keyword>Squamous NSCLC</keyword>
</DOC>